This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06942/identifier/pdb/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06942/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06942/identifier/pubchem-substance/
n6http://linked.opendata.cz/resource/drugbank/drug/DB06942/identifier/drugbank/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB06942
rdf:type
n3:Drug
n3:description
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-l-prolinamide is a solid. This compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.
n3:group
experimental
owl:sameAs
n9:DB06942 n12:DB06942
dcterms:title
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide
adms:identifier
n6:DB06942 n7:99443413 n11:27U n13:25113615
n3:IUPAC-Name
n4:271B610E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6114-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6113-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6110-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6111-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6112-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B610C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B610A-363D-11E5-9242-09173F13E4C5 n4:271B610D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B610B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B611A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B611B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6115-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6116-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6118-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6117-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6119-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6120-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6122-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6123-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B611F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B611E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6121-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B610F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B611C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B611D-363D-11E5-9242-09173F13E4C5